Cargando…

Clinical Effect of Early vs Late Amyloid Positron Emission Tomography in Memory Clinic Patients: The AMYPAD-DPMS Randomized Clinical Trial

IMPORTANCE: Amyloid positron emission tomography (PET) allows the direct assessment of amyloid deposition, one of the main hallmarks of Alzheimer disease. However, this technique is currently not widely reimbursed because of the lack of appropriately designed studies demonstrating its clinical effec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Altomare, Daniele, Barkhof, Frederik, Caprioglio, Camilla, Collij, Lyduine E., Scheltens, Philip, Lopes Alves, Isadora, Bouwman, Femke, Berkhof, Johannes, van Maurik, Ingrid S., Garibotto, Valentina, Moro, Christian, Delrieu, Julien, Payoux, Pierre, Saint-Aubert, Laure, Hitzel, Anne, Molinuevo, José Luis, Grau-Rivera, Oriol, Gispert, Juan Domingo, Drzezga, Alexander, Jessen, Frank, Zeyen, Philip, Nordberg, Agneta, Savitcheva, Irina, Jelic, Vesna, Walker, Zuzana, Edison, Paul, Demonet, Jean-François, Gismondi, Rossella, Farrar, Gill, Stephens, Andrew W., Frisoni, Giovanni B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2023
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10167601/ https://www.ncbi.nlm.nih.gov/pubmed/37155177 http://dx.doi.org/10.1001/jamaneurol.2023.0997

Ejemplares similares

Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study
por: Lopes Alves, Isadora, et al.
Publicado: (2020)

Analysis of Psychological Symptoms Following Disclosure of Amyloid–Positron Emission Tomography Imaging Results to Adults With Subjective Cognitive Decline
por: Caprioglio, Camilla, et al.
Publicado: (2023)

Quantification of amyloid PET for future clinical use: a state-of-the-art review
por: Pemberton, Hugh G., et al.
Publicado: (2022)

The Clinical Use of Alzheimer’s Disease Biomarkers in Patients with Mild Cognitive Impairment: A European Alzheimer’s Disease Consortium Survey
por: Caprioglio, Camilla, et al.
Publicado: (2022)

A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [(18)F]flutemetamol amyloid PET images
por: Bucci, Marco, et al.
Publicado: (2021)

Clinical impact of [(18)F]flutemetamol PET among memory clinic patients with an unclear diagnosis
por: Leuzy, Antoine, et al.
Publicado: (2019)

Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Chiotis, Konstantinos, et al.
Publicado: (2021)

Eigenvector centrality dynamics are related to Alzheimer’s disease pathological changes in non-demented individuals
por: Lorenzini, Luigi, et al.
Publicado: (2023)

Clinical validity of increased cortical uptake of [(18)F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework
por: Wolters, E. E., et al.
Publicado: (2021)

Innovative Molecular Imaging for Clinical Research, Therapeutic Stratification, and Nosography in Neuroscience
por: Beaurain, Marie, et al.
Publicado: (2019)

Recruitment of pre-dementia participants: main enrollment barriers in a longitudinal amyloid-PET study
por: Bader, Ilse, et al.
Publicado: (2023)

The amyloid imaging for the prevention of Alzheimer's disease consortium: A European collaboration with global impact
por: Collij, Lyduine E., et al.
Publicado: (2023)

Personalized risk for clinical progression in cognitively normal subjects—the ABIDE project
por: van Maurik, Ingrid S., et al.
Publicado: (2019)

Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Bischof, Gérard N, et al.
Publicado: (2021)

Prognostic value of imaging-based ATN profiles in a memory clinic cohort
por: Peretti, Débora E., et al.
Publicado: (2023)

Clinical outcomes up to 9 years after [(18)F]flutemetamol amyloid-PET in a symptomatic memory clinic population
por: Collij, Lyduine E., et al.
Publicado: (2023)

2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Leuzy, A., et al.
Publicado: (2021)

Impact of cerebral blood flow and amyloid load on SUVR bias
por: Heeman, Fiona, et al.
Publicado: (2022)

Visual assessment of [(18)F]flutemetamol PET images can detect early amyloid pathology and grade its extent
por: Collij, Lyduine E., et al.
Publicado: (2021)

The taxonomy of subjective cognitive decline: proposal and first clinical evidence from the Geneva memory clinic cohort
por: Ribaldi, Federica, et al.
Publicado: (2023)

Clinical impact of (18)F-FDG-PET among memory clinic patients with uncertain diagnosis
por: Perini, Giulia, et al.
Publicado: (2020)

Protocols for cognitive enhancement. A user manual for Brain Health Services—part 5 of 6
por: Brioschi Guevara, Andrea, et al.
Publicado: (2021)

Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline
por: Ebenau, Jarith L., et al.
Publicado: (2022)

Clinical utility of FDG PET in Parkinson’s disease and atypical parkinsonism associated with dementia
por: Walker, Zuzana, et al.
Publicado: (2018)

Brain Health Services: organization, structure, and challenges for implementation. A user manual for Brain Health Services—part 1 of 6
por: Altomare, Daniele, et al.
Publicado: (2021)

Clinical heterogeneity of neuro-inflammatory PET profiles in early Alzheimer’s disease
por: Gouilly, Dominique, et al.
Publicado: (2023)

Strategies to reduce sample sizes in Alzheimer’s disease primary and secondary prevention trials using longitudinal amyloid PET imaging
por: Lopes Alves, Isadora, et al.
Publicado: (2021)

Dementia prevention in memory clinics: recommendations from the European task force for brain health services
por: Frisoni, Giovanni B., et al.
Publicado: (2023)

PET metabolic tumor volume as a new prognostic factor in childhood rhabdomyosarcoma
por: Fayolle, Helio, et al.
Publicado: (2022)

Spatial-Temporal Patterns of β-Amyloid Accumulation: A Subtype and Stage Inference Model Analysis
por: Collij, Lyduine E., et al.
Publicado: (2022)

The impact of a multi-domain intervention on cerebral glucose metabolism: analysis from the randomized ancillary FDG PET MAPT trial
por: Delrieu, Julien, et al.
Publicado: (2020)

Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging
por: Chiotis, Konstantinos, et al.
Publicado: (2015)

Amyloid‐β PET and CSF in an autopsy‐confirmed cohort
por: Reimand, Juhan, et al.
Publicado: (2020)

Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives
por: Cotta Ramusino, Matteo, et al.
Publicado: (2021)

Pharmacological Characterization of [(18)F]-FNM and Evaluation of NMDA Receptors Activation in a Rat Brain Injury Model
por: Beaurain, Marie, et al.
Publicado: (2023)

Regional Disconnection in Alzheimer Dementia and Amyloid-Positive Mild Cognitive Impairment: Association Between EEG Functional Connectivity and Brain Glucose Metabolism
por: Smailovic, Una, et al.
Publicado: (2020)

Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison
por: Altomare, Daniele, et al.
Publicado: (2021)

Does Early Treatment Improve Clinical Outcome of Class II Patients? A Retrospective Study
por: Männchen, Roland, et al.
Publicado: (2022)

Clinical review: Airway hygiene in the intensive care unit
por: Jelic, Sanja, et al.
Publicado: (2008)

Biomarker testing in MCI patients—deciding who to test
por: van Maurik, Ingrid S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7lputcktp7mum0o7l30jtqpq57